S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
Log in

Turning Point Therapeutics Stock Price, News & Analysis (NASDAQ:TPTX)

$36.99
+0.70 (+1.93 %)
(As of 10/16/2019 04:00 PM ET)
Today's Range
$35.80
Now: $36.99
$37.36
50-Day Range
$36.06
MA: $42.15
$57.10
52-Week Range
$24.21
Now: $36.99
$58.56
Volume348,759 shs
Average Volume229,231 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TPTX
CUSIPN/A
CIKN/A
Phone858-926-5251

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees50
Market Cap$1.16 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable

Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter.


Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics (NASDAQ:TPTX) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.05. View Turning Point Therapeutics' Earnings History.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Turning Point Therapeutics.

What price target have analysts set for TPTX?

9 brokerages have issued 1-year price objectives for Turning Point Therapeutics' shares. Their predictions range from $42.00 to $70.00. On average, they expect Turning Point Therapeutics' share price to reach $54.56 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price. View Analyst Price Targets for Turning Point Therapeutics.

What is the consensus analysts' recommendation for Turning Point Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Turning Point Therapeutics.

Has Turning Point Therapeutics been receiving favorable news coverage?

Headlines about TPTX stock have been trending very positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Turning Point Therapeutics earned a news impact score of 3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Turning Point Therapeutics.

Are investors shorting Turning Point Therapeutics?

Turning Point Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,280,000 shares, an increase of 17.5% from the August 30th total of 1,940,000 shares. Based on an average daily trading volume, of 224,000 shares, the days-to-cover ratio is presently 10.2 days. Currently, 10.6% of the shares of the company are short sold. View Turning Point Therapeutics' Current Options Chain.

Who are some of Turning Point Therapeutics' key competitors?

What other stocks do shareholders of Turning Point Therapeutics own?

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the folowing people:
  • Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)
  • Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)
  • Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)
  • Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
  • Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec.

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

When did Turning Point Therapeutics' lock-up period expire?

Turning Point Therapeutics' lock-up period expired on Monday, October 14th. Turning Point Therapeutics had issued 9,250,000 shares in its public offering on April 17th. The total size of the offering was $166,500,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $36.99.

How big of a company is Turning Point Therapeutics?

Turning Point Therapeutics has a market capitalization of $1.16 billion. Turning Point Therapeutics employs 50 workers across the globe.View Additional Information About Turning Point Therapeutics.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is http://www.tptherapeutics.com/.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]


MarketBeat Community Rating for Turning Point Therapeutics (NASDAQ TPTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  46
MarketBeat's community ratings are surveys of what our community members think about Turning Point Therapeutics and other stocks. Vote "Outperform" if you believe TPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Blockchain

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel